- ASSOCIATE PROFESSOR | Medicine, Rheumatology
- Hospital Affiliations
- Mount Sinai St. Luke's and Mount Sinai West
- The Mount Sinai Hospital
Dr. Ali is an Associate Professor in the Mount Sinai Department of Medicine and Chief of the Division of Rheumatology at Mount Sinai West. He is a graduate of the Royal Free Hospital School of Medicine in London. After two years of postgraduate training in the UK, he moved to the US and did his Internal Medicine training at OHSU in Portland, Oregon. He completed his fellowship training in Rheumatology at Yale University and is board certified in both Rheumatology and Internal Medicine. For three years he was the Vice Chair of Faculty Affairs in the Department of Medicine.
Prior to Mount Sinai, Dr. Ali was in practice in Providence, Rhode Island for nine years, where he was an Assistant Clinical Professor of Medicine at Brown University. He is the recipient of a multitude of awards, including the prestigious Beckwith Family award for outstanding teaching. He has published numerous articles, book chapters, and has lectured widely on Rheumatoid arthritis, Osteoporosis, Gout and Osteoarthritis. His current research involves cardiovascular inflammation as it relates to Gout and he is PI on several studies including novel anticytokine targets in non-radiographic spondyloarthropathy and the role of PET imaging in patients with Rheumatoid Arthritis.
Read Dr. Ali's blog on psoriatic arthritis here.
American Board of Internal Medicine
- Ankylosing Spondylitis
- Behcet's Disease
- Polymyalgia Rheumatica And Giant Cell Arteritis
- Reiter's Syndrome
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Systemic Lupus Erythematosus
- Temporal Arteritis
- Wegener's Granulomatosis
BM, Royal Free Hospital Sch of Medicine
MD, Royal Free Hospital School of Medicine. University of London
Residency, Internal Medicine
Oregon Health Sciences University
* Yale University School of Medicine *
Stanley G. Seckler Award for Clinical and Educational Excellence in Medicine
Best Doctors in NY
Best Doctors in Rhode Island
Beckwith Family Award for outstanding teaching
Teaching Recognition Award
Top Doctors in New York
Dr Ali is currently PI on several trials investigating new treatments for SLE and RA. He is also developing a patient centric app to predict flares in RA that should improve care and outcome.
Embrace Study: phase 3/4, multi-center, randomized, double-blind, placebo-controlled,52-week study to evaluate the efficacy and safety of belimumab (HGS1006) in adult subjects of black race with SLE
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti-TNF Therapy
A Phase 3/4 Multi-Center Randomized Double-Blind Placebo Controlled 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus (SLE)
The purpose of this study is to find out if Belimumab is effective and safe in treating patients of black race who have lupus and are receiving other lupus medicines. Lupus occurs more frequently in people of black race and when it does occur it is often more severe. In ...
A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active non-radiographic axial spondyloarthritis
If subjects agree to join in this study, they may get either secukinumab 150 mg or a placebo for the first 52 weeks of the study. At the start of the trial, there is a 2 to 1 chance of receiving either secukinumab or placebo with no medicine. After 20 weeks, their disease status ...
Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)
The purpose of this research study to find out the link between rheumatoid arthritis (RA) and vascular inflammation. Also to learn whether increased systemic inflammation causes cardiovascular diseases (CVD), and which treatment approach, TNF inhibitors or Triple Therapy, will ha...
Hyaluronan Injections for Osteoarthritis of the Knee [review]. Med Lett Drugs Ther.; 40(1030).
Refractory Scleritis Associated with Hepatitis C and Cyroglobulinemia. J Clinical Rheumatology 1999 December;.
Acute pseudogout following intr-articular injection of high molecular weight hyaluronic acid. Am J Med 1999 December ; 107(6): 641-642.
Infliximab induced SLE. Annals Internal Medicine 2002 October; 137(7): 625-626.
Always trust your gut feeling. The Lancet 2005 March; 365(9465): 1201.
Ali Y, Perlman E. Successful treatment of refractory sarcoid associated uveitis with Inflixmab. Annals of Internal Medicine 2004 June; 140(3465): no.11 W-48.
Ali . Self Assessment Questions in Rheumatology . Humana Press;.
Evaluation of the patient with Musculoskeletal symptoms. In: Hand Surgery. LWW Book; pp625-628.
Gout and Pseudogout: Primary Care for Women. Lippincott Williams & Wilkins 2nd Edition; pp633-636.
Aaron RK, Voisinet A, Racine J, Ali Y, Feller ER. Corticosteroid-associated avascular necrosis: dose relationships and early diagnosis. Annals of the New York Academy of Sciences 2011 Dec; 1240.
Bartov JB, Ali Y. Successful use of the interleukin 1 antagonist, anakinra, in a patient with gout, chronic kidney disease, and aplastic anemia. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2013 Dec; 19(8).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Ali did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.